Judge OKs $264M Deal Ending Mylan EpiPen Price-Hike Suit

By Jonathan Capriel (March 14, 2022, 9:01 PM EDT) -- A Kansas federal court has preliminarily approved a $264 million deal that would end claims that Mylan colluded with Pfizer Inc. to obstruct generic versions of the EpiPen, the emergency drug used to treat severe allergic reactions, from entering the market....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!